title: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
abstract: Iron supplementation is required by most dialysis patients receiving recombinant human erythropoietin. The efficacy of oral iron is variable in these patients, and many require the use of intravenous iron dextran to maintain adequate iron levels, defined as transferrin saturation greater than 20%, serum ferritin greater than 100 ng/mL, and serum iron greater than 80 micrograms/dL. To determine the efficacy of different oral iron preparations in maintenance of iron status, we prospectively studied 46 recombinant human erythropoietin-treated patients and randomized them to receive different oral iron preparations. These four preparations included Chromagen (ferrous fumarate; Savage Laboratories, Melville, NY), Feosol (ferrous sulfate; SmithKline Beecham, Inc, Pittsburgh, PA), Niferex (polysaccharide; Central Pharmaceuticals, Inc, Seymour, IN), or Tabron (ferrous fumarate; Parke-Davis, Morris Plains, NJ). All patients were prescribed approximately 200 mg of elemental iron daily of their assigned iron preparation with at least 100 mg ascorbic acid daily for 6 months. At baseline and bimonthly during the study, serum iron, transferrin saturation, ferritin, hematocrit, and recombinant human erythropoietin dose were monitored; in addition, compliance and side effects were recorded by patient interview. All patients were able to maintain target hematocrit during the 6 months of study. However, there were differences in the trends of serum iron, percent transferrin saturation, and ferritin when considered singly or in combination between the four groups of iron medications. The percent of laboratory values measured over the study period in each group that met the criteria of transferrin saturation more than 20% was greatest in the Tabron group (58%), followed by the Feosol (47%), Chromagen (33%), and Niferex (31%) groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2372.
authors.forename: R L
authors.initials: RL
authors.lastname: Wingard
authors.forename: R A
authors.initials: RA
authors.lastname: Parker
authors.forename: N
authors.initials: N
authors.lastname: Ismail
authors.forename: R M
authors.initials: RM
authors.lastname: Hakim
mesh_terms: D000284:Administration, Oral; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D018798:Anemia, Iron-Deficiency / Q000517:prevention & control; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage; D006400:Hematocrit; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011134:Polysaccharides / Q000008:administration & dosage; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D003692:Delayed-Action Preparations; D005296:Ferrous Compounds; D011134:Polysaccharides; D011994:Recombinant Proteins; D004921:Erythropoietin; C020748:ferrous sulfate; C078972:Niferex; D007501:Iron; C031621:ferrous fumarate